AZD-5153
- Generic Name
- AZD-5153
- Drug Type
- Small Molecule
- Chemical Formula
- C25H33N7O3
- CAS Number
- 1869912-39-9
- Unique Ingredient Identifier
- C7C7U6YEAO
Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)
Phase 1
Completed
- Conditions
- Non-hodgkin's LymphomaDiffuse Large B Cell LymphomaNHLDLBCL
- Interventions
- First Posted Date
- 2018-05-17
- Last Posted Date
- 2022-08-15
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 30
- Registration Number
- NCT03527147
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas
Phase 1
Completed
- Conditions
- Malignant Solid TumorsLymphomaOvarian CancerProstate CancerBreast CancerPancreatic Cancer
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2021-05-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 49
- Registration Number
- NCT03205176
- Locations
- 🇨🇦
Research Site, Toronto, CA, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath